Published in Circ Res on October 27, 2005
Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthritis Cartilage (2007) 1.69
C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med (2007) 1.64
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. J Clin Endocrinol Metab (2009) 1.27
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol (2008) 1.21
Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology (2006) 1.16
Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol (2008) 1.14
Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One (2008) 1.09
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol (2007) 1.00
C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol (2008) 0.94
Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem (2011) 0.92
C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta. Am J Physiol Heart Circ Physiol (2008) 0.88
Atherosclerosis-related functions of C-reactive protein. Cardiovasc Hematol Disord Drug Targets (2010) 0.87
Endogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils through Different Receptors. Front Immunol (2013) 0.86
Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum (2010) 0.85
New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging (2008) 0.83
Interpretation of C-reactive protein concentrations in critically ill patients. Biomed Res Int (2013) 0.81
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods (2012) 0.81
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes. Mediators Inflamm (2015) 0.80
Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting. Anesthesiology (2010) 0.80
A proteomic analysis of C-reactive protein stimulated THP-1 monocytes. Proteome Sci (2011) 0.77
In vivo effects of C-reactive protein (CRP)-infusion into humans. Circ Res (2005) 0.77
Serum C-Reactive Protein (CRP), Target for Therapy or Trouble? Biomark Insights (2007) 0.77
Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microb Cell Fact (2016) 0.76
C-reactive protein does not impair insulin suppression of glucose release in primary hepatocytes. Nutr Metab Cardiovasc Dis (2010) 0.75
Study of High Sensitive C-Reactive Protein (HS-CRP) After Cardiac Rehabilitation Program in Patients Undergoing Isolated CABG. Int J Biomed Sci (2016) 0.75
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science (1999) 7.75
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest (1993) 2.92
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol (2005) 2.64
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis (1999) 1.96
Toll-like receptors are temporally involved in host defense. J Immunol (2004) 1.93
Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci (2001) 1.89
Distribution of C-reactive protein values in the United States. N Engl J Med (2005) 1.69
Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine (1992) 1.64
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62
Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. Clin Chem (2004) 1.57
Primary structure of human C-reactive protein. J Biol Chem (1979) 1.55
Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation (2005) 1.33
C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med (2004) 1.26
Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation (2004) 1.26
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab (2004) 1.21
Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. J Exp Med (1984) 1.17
Isolation and study of murine C3. Immunology (1977) 1.13
Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal (1998) 1.11
Real-time measurement of serum C-reactive protein in the management of infection in the elderly. Age Ageing (1986) 1.09
Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis (1981) 0.98
In vivo turnover studies of C-reactive protein. Clin Exp Immunol (1985) 0.96
C-reactive protein in patients undergoing cardiac surgery. Anaesthesia (1986) 0.90
Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol (2005) 0.90
C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol (2004) 0.90
C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol (2004) 0.89
Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. Age Ageing (1997) 0.89
C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol (2004) 0.88
Quantitative determination of individual serum proteins by radio-electroimmuno and use of 125 I-labelled antibodies (application to C-reactive protein). Scand J Clin Lab Invest Suppl (1972) 0.87
Effect of bacterial endotoxin on body temperature, plasma zinc and plasma concentrations of the acute-phase protein serum amyloid p component in mice. Br J Exp Pathol (1984) 0.84
Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol (1993) 0.83
Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization. Biochem Biophys Res Commun (2002) 0.83
Letter regarding article by Li et al, "C-reactive protein upregulates complement-inhibitory factors in endothelial cells.". Circulation (2004) 0.81
Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. Biochem Biophys Res Commun (2004) 0.81
Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice. Br J Exp Pathol (1980) 0.80
Detection of endotoxin in mice by measurement of endotoxin-induced changes in plasma concentrations of zinc and of the acute-phase protein serum amyloid P-component. J Pharm Pharmacol (1986) 0.79
Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. J Clin Pathol (1985) 0.78
Neutrophil extracellular traps kill bacteria. Science (2004) 23.64
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Novel cell death program leads to neutrophil extracellular traps. J Cell Biol (2007) 10.92
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog (2009) 5.40
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A (2010) 5.05
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol (2007) 4.65
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol (2010) 4.50
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol (2006) 4.47
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood (2009) 4.06
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol (2006) 3.69
Neutrophil function: from mechanisms to disease. Annu Rev Immunol (2012) 3.63
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr (2007) 3.40
Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol (2012) 3.39
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood (2010) 3.23
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet (2005) 3.01
NETs: a new strategy for using old weapons. Trends Immunol (2009) 2.98
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol (2008) 2.72
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity (2006) 2.61
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS (2006) 2.42
Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol (2010) 2.39
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection. Infect Immun (2006) 2.35
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood (2010) 2.32
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Neutrophil elastase targets virulence factors of enterobacteria. Nature (2002) 2.17
Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem (2003) 2.15
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Newly diagnosed HIV infections: review in UK and Ireland. BMJ (2005) 2.00
Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol (2007) 1.99
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry (2013) 1.95
Toll-like receptors are temporally involved in host defense. J Immunol (2004) 1.93
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.83
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS (2005) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80
Mouse neutrophil extracellular traps in microbial infections. J Innate Immun (2009) 1.79
Neutrophil extracellular traps: how to generate and visualize them. J Vis Exp (2010) 1.77
The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J Hepatol (2008) 1.76
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS (2002) 1.74
How do microbes evade neutrophil killing? Cell Microbiol (2006) 1.73
In-training assessment for specialist registrars: views of trainees and trainers in the Mersey Deanery. J R Soc Med (2002) 1.72
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70
Can sutures get wet? Prospective randomised controlled trial of wound management in general practice. BMJ (2006) 1.67
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62